**Platelet Additive Solution SSP+**

*Safe platelets through saved plasma*

**BENEFITS**

- Reduce plasma volume to decrease adverse events (TRALI*, ABO mismatch).
- Compatible with Pathogen Reduction Treatment.
- Improved bacterial detection performance.
- Reduction of discard-rate due to expiry: compatibility with extended platelet shelf life** up to 7 days.
- Having a large volume of available plasma as a transfusable product or for fractionation.
- Compatible with all technologies for preparation of platelet products (eg. automated devices for whole blood and apheresis derived platelets).

**EXTENDED PROCESSING CONDITIONS**

The Platelet Additive Solution SSP+ (PAS III-M/E*** generation) was developed to improve storage stability of buffy-coat and apheresis Platelet Concentrates for up to seven days with maximum ratio of up to 80% SSP+ / 20% plasma.

Since 2002, Macopharma has brought clinical & logistical benefits to patients and blood banks with over 3 million units of Platelet Additive Solution distributed worldwide.

---

*Transfusion Acute Lung Injuries
**Platelets should not be stored for more than 5 days unless bacterial detection or reduction methods are used.
***ISBT 128 Terminology for Platelet Additive Solutions
PERFORMANCE

SSP+ is recognized as the most suitable additive solution on the market that helps standardise platelet concentrates and improves storage conditions. In vitro quality and post-transfusion recovery of SSP+ platelets is well maintained. Both, Buffy-Coat and Apheresis derived platelets perform at least as well as platelets stored in 100% plasma.

In vitro quality of Buffy Coat derived platelets (data provided by Red Cross Blood Services NSTOB, Springe, Germany)

Go to [www.macopharma.com](http://www.macopharma.com) to get a complete overview of our products.

SSP+ is a CE marked Class III Medical Device.
It is not available for sale in the United States.
Please refer to the Instructions for Use.

MACOPHARMA
Rue Lorthios
F-59420 Mouvaux (France)
www.macopharma.com